The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions.

doi:10.1016/j.ejca.2022.04.020

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions.

European journal of cancer (Oxford, England : 1990) - 1 Jul 2022

Christopoulos Petros, Kluck Klaus, Kirchner Martina, Lüders Heike, Roeper Julia, Falkenstern-Ge Roger-Fei, Szewczyk Marlen, Sticht Florian, Saalfeld Felix C, Wesseler Claas, Hackanson Björn, Dintner Sebastian, Faehling Martin, Kuon Jonas, Janning Melanie, Kauffmann-Guerrero Diego, Kazdal Daniel, Kurz Sylke, Eichhorn Florian, Bozorgmehr Farastuk, Shah Rajiv, Tufman Amanda, Wermke Martin, Loges Sonja, Brueckl Wolfgang M, Schulz Christian, Misch Daniel, Frost Nikolaj, Kollmeier Jens, Reck Martin, Griesinger Frank, Grohé Christian, Hong Jin-Liern, Lin Huamao M, Budczies Jan, Stenzinger Albrecht, Thomas Michael

Abstract excerpt

BACKGROUND: EGFR exon20 insertions (ex20ins) are targeted by novel compounds in non-small-cell lung cancer (NSCLC). However, data about outcome under conventional therapies and the influence of molecular features are scarce. PATIENTS AND METHODS: We retrospectively analysed 118 patients with evaluation of radiologic response based on RECIST v1.1. TP53 status was available for 88 cases. RESULTS: Platinum doublets...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents

Share to Brain Neoplasms

Share to Carcinoma, Non-Small-Cell Lung

Share to ErbB Receptors

Share to Platinum

Share to Protein Kinase Inhibitors

Share to Tumor Microenvironment

Share to Tumor Suppressor Protein p53

Source

Open in PubMed

Identifiers

PMID: 35598358
DOI: 10.1016/j.ejca.2022.04.020

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The impact of TP53 co-mutations and immunologic microenvironment on outcome of lung cancer with EGFR exon 20 insertions.PMID 35598358Read ↗

Immune microenvironment features and efficacy of PD‐1/PD‐L1 blockade in non‐small cell lung cancer patients with EGFR or HER2 exon 20 insertionsSemantic proximity Read ↗

Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions.Semantic proximity Read ↗

Analysis of the efficacy and influencing factors of double-dose furmonertinib for advanced EGFR ex20ins non-small cell lung cancer.Semantic proximity Read ↗

Poor efficacy of immune checkpoint inhibitors plus chemotherapy in the lung cancer patients with EGFR/ERBB2 exon 20 insertionSemantic proximity Read ↗

Characteristics, treatment patterns, and clinical outcomes in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertions.Semantic proximity Read ↗

Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimenSemantic proximity Read ↗

EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy.Semantic proximity Read ↗

Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertionsSemantic proximity Read ↗

The role of distinct co-mutation patterns with TP53 mutation in immunotherapy for NSCLCSemantic proximity Read ↗

First-line treatment for driver gene–negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab？Semantic proximity Read ↗

Durable Response to Immunotherapy Plus Chemotherapy in a Patient With Untreated, Brain-metastatic, EGFR Exon 20 Insertion Mutation Lung AdenocarcinomaSemantic proximity Read ↗

Prognostic implications of combining EGFR-TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19-Del or 21-L858R mutations: A real-world study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.